Survival of patients with spinal muscular atrophy type 1 by Gregoretti, C. et al.
Survival of Patients With Spinal Muscular
Atrophy Type 1
WHAT’S KNOWN ON THIS SUBJECT: Survival of children with
spinal muscular atrophy type 1 is determined by treatment
choice: tracheostomy with mechanical ventilation, noninvasive
mechanical ventilation, or a palliative approach. Few data are
available on life expectancies with different approaches.
WHAT THIS STUDY ADDS: The present study provides data
comparing therapeutic strategies that affect life expectancy.
Clinicians involved in the care of patients with spinal muscular
atrophy type 1 should be aware of survival trends while awaiting
more deﬁnitive therapeutic strategies.
abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progres-
sive disease and is usually fatal in the ﬁrst year of life.
METHODS: A retrospective chart review was performed of SMA1
patients and their outcomes according to the following choices: let-
ting nature take its course (NT); tracheostomy and invasive mechan-
ical ventilation (TV); continuous noninvasive respiratory muscle aid
(NRA), including noninvasive ventilation; and mechanically assisted
cough.
RESULTS: Of 194 consecutively referred patients enrolled in this study
(103 males, 91 females), NT, TV, and NRA were chosen for 121 (62.3%),
42 (21.7%), and 31 (16%) patients, respectively. Survival at ages 24 and
48 months was higher in TV than NRA users: 95% (95% conﬁdence in-
terval: 81.8%–98.8%) and 67.7% (95% conﬁdence interval: 46.7%–82%)
at age 24 months (P , .001) and 89.43% and 45% at age 48 months in
the TV and NRA groups, respectively (P , .001). The choice of TV
decreased from 50% (1992–1998) to 12.7% (2005–2010) (P , .005)
with a nonstatistically signiﬁcant increase for NT from 50% to 65%.
The choice of NRA increased from 8.1% (1999–2004) to 22.7% (2005–
2010) (P , .001).
CONCLUSIONS: Long-term survival outcome is determined by the
choice of the treatment. NRA and TV can prolong survival, with NRA
showing a lower survival probability at ages 24 and 48 months.
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Spinal muscular atrophy (SMA) type 1
(SMA1; Werdnig-Hoffmann disease) is
the second most common, potentially
lethal autosomal recessive disorder,
affecting1of6 to8 livebirthsandhasa1
in34asymptomaticcarrier frequency.1,2
SMA ranges in severity from severe
weakness and deﬁnitive need for ven-
tilatory support as newborns to mus-
cle weakness ﬁrst seen in adulthood.
Patients with SMA type 3 develop the
ability to walk independently for some
period of time. Patients with SMA type 2
never walk but are able to sit in-
dependently for some period of time.
Children with SMA1 can never roll, sit, or
walk. SMA1 is a progressive disease3–5
and is usually fatal in infancy.6,7 SMA1
can be additionally subdivided by se-
verity according to the age at ﬁrst
manifestation of clinical symptoms.8 It
can be deﬁned as “true” when the onset
of clinical symptoms is before 3 months
of age with the inability to raise the head
and as “intermediate”when the onset of
symptoms is after 3 months of age with
the ability to raise the head. The con-
dition’s severity can be ranked as “se-
vere 1A”, “typical 1A,” or “mild 1B”,
according to the age at ﬁrst episode of
respiratory decompensation. In the
most severe phenotype, 24 hours of
mechanical ventilation per day are
needed before 6 months of age.9–11 New
management approaches have already
been described in SMA1, with children
becoming dependent on continuous
noninvasive respiratory aid.9,12,13 Its
aim was to provide periods of rest
for inspiratory muscles, to promote
lung growth, and to prevent pectus
excavatum14 to maximize cough ﬂows
and maintain normal alveolar ventila-
tion11. In addition, it can be used in the
postextubation periodwhen patients are
recovering from an acute episode of
respiratory failure requiring airway in-
tubation15,16. “Symptomatic treatment”
as well as low pressure values of bilevel
ventilation are inadequate for advanced
patients.17
The purpose of this study was to de-
scribe the outcome according to the
choice of treatment and changes in the
SMA patient’s life and to compare these
ﬁndings with previously reported sur-
vival patterns.
METHODS
The medical records of all patients af-
fected by SMA1, followed up by 4 Italian
centers from October 1, 1992, to De-
cember 31, 2010, were reviewed. The
diagnoses were made during the early
1990s by clinical and electrophysiologic
study and, as early as it was available,
by genetic study. The severity of the
patients’ phenotypes was classiﬁed
for all patients according to age at
ﬁrst clinical symptoms8 and, for the
mechanically ventilated patients only,
to age at ﬁrst respiratory decom-
pensation.13 The study was approved
by local ethical committe at Bambino
Gesù Children’s Hospital, as a survey of
Sma type 1 children.
The exclusion criterion was diagnoses
performedafter the ninthmonthsof age,
because older children could have been
able to sit andsomaynothavehadSMA1.
Data pertaining to relevant variables
were obtained from medical records or
fromanonlineservice.They includeddate
of birth, age at ﬁrst clinical symptoms,
choice of treatment, and date of death, if
applicable. Age at ﬁrst respiratory de-
compensation was obtained only for the
mechanically ventilated patients.
Parents were given the following
choices: (1) to “let nature take its
course,” meaning to provide support-
ive care only (no treatment [NT]); (2) to
perform elective tracheostomy and in-
vasive mechanical ventilation (TV); and
(3) only from January 1999 to use
noninvasive respiratory aid (NRA). NRA
consisted of noninvasive bilevel venti-
lation (NIV) and mechanically assisted
coughing (MAC). Invasive ventilation,
MAC, and NIV were applied as pre-
viously described.9–12,15–21 Equipment
at home consisted of 2 mechanical
ventilators, 2 vacuum-operatedmachines
for aspirating oral and bronchial
secretions, 1 MAC machine functioning
both in manual and in automatic mode,
1 pulse oximeter, 1 active humidiﬁer for
mechanical ventilation, and 1 manual
resuscitator bag.
Parents choosing long-term ventilation
were instructed in the hospital setting
in basic life support and in treating
respiratory decompensation. After 2002
we adopted the protocol published by
Gomez-Merino and Bach20 for the use of
respiratory muscle aid by using oxime-
try feedback.
During acute episodes of acute re-
spiratory decompensation, peripheral
hemoglobin pulse oxygen saturation
(SpO2) was continuously monitored.
Aggressive MAC, postural drainage,
and deep airway suctioning were used
when SpO2 fell below 95%. Broad-
spectrum antibiotics were prescribed.
Parents were allowed to increase NIV
peak pressure up to 25 cm H2O in the
presence of desaturation, to increase
the back-up ventilator rate to avoid
patient-ventilator asynchrony, and to
use MAC until SpO2 normalized. Par-
ents could also increase insufﬂator-
exsufﬂator pressures as previously
described.12 Patients who needed in-
tubation for acute respiratory failure
were extubated to NIV/MAC to their
premorbid settings according to an
already described extubation pro-
tocol.9 Atropine was administered to
reduce oropharyngeal secretions. Sup-
plemental oxygen was usually avoided
at home. Parents were advised to use it
during secretion mobilization and
periods of respiratory arrest.12
All patients were surveyed for the oc-
currence of respiratory tract infections
causing desaturation, continuous ap-
plication of NIV, and need for hospital
admission. Respiratory tract infections
were deﬁned by the presence of fever
and mucopurulent sputum with an SpO2
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,95%. Other respiratory complications
such as pneumothorax and pneumo-
mediastinumwere taken into account.22
Acute episodes of respiratory de-
compensation were indicated by wors-
ening of paradoxical breathing and
episodes of transcutaneous SpO2,95%
lasting several minutes with the
need for continuous NIV to avoid re-
spiratory distress and desaturation.13
Respiratory arrest was deﬁned by ap-
nea and desaturation ,40% reversed
only by basic life support.23 Avoided
hospitalization was deﬁned by man-
agement of the patient’s desaturations
at home with a continuous application
of NIV and frequent use of MAC.16 Acute
respiratory failure in the hospital set-
tingwasdeﬁned by respiratory distress,
tachypnea, and severe gas-exchange
derangement. Hypoxemia was deﬁned
by SpO2 ,95% despite an oxygen in-
spired fraction .0.5. Respiratory aci-
dosis was deﬁned as an increase in
PaCO2 causing a pH,7.35.
Statistical Analysis
Categorical variables were compared
through x2 or Fisher’s exact test when
appropriate. Continuous variables were
represented by means and SD or
medians and range, and analyzed by
t test and analysis of variance or Mann-
Whitney and Friedman tests as needed.
The survival experience of patients was
analyzed by using the Kaplan-Meier
method. A comparison of the survival
curve estimates for each of the 3 groups
of patients (NT, NRA, TV) was made by
log-rank test. SMA severity according to
the age at ﬁrst respiratory decompen-
sation between the NRA and TV groups was
compared by Fisher’s exact test. The x2 for
trend test was used to evaluate the trend
of proportions over time. Statistical analy-
sis was performed by using Stata, version
11.2 (StataCorp LP, College Station, TX).
RESULTS
Of 219 patients initially analyzed, 14
were excluded because of late and in-
adequate diagnoses and 11 patients
were excluded due to incomplete data.
One hundred ninety-four patients who
satisﬁed thecriteria forSMA1diagnosis
were considered eligible. All patients
were discharged from the hospital.
Parents were trained for a predeﬁned
period at a training center. This center
was also in charge of setting up the
home care program.
NTwas used in 121 patients (62.3%) (70
males and 51 females), TV in 42 patients
(21.7%) (19 males and 23 females), and
NRA in 31 patients (16%) (14 males and
17 females). Table 1 shows the classi-
ﬁcation of SMA severity according to
the age at onset of clinical symptoms.9
No differences between the 4 hospitals
could be found.
The proportion of patients with “true”
SMA1 was higher in the NT group com-
pared with NRA and TV (NT versus NRA,
P , .01; NT versus TV, P , .01). No sig-
niﬁcant difference regarding the pro-
portion of “true” and “intermediate”
SMA1 was found between NRA and TV
groups.
Table 2 shows the classiﬁcation of SMA
severity according to age at ﬁrst re-
spiratory decompensation.17 The mean
age at ﬁrst respiratory decompensation
was 6.96 4.3 and 12.66 14.4 months in
the TV and NRA groups, respectively (P =
.004). One patient in the NRA group
needed mechanical ventilation from
birth, and 1 patient needed mechanical
ventilation at the age of 42 months.
Interestingly, 6 patients in the NRA
group (19.3%) did not showany episode
of respiratory decompensation and
avoided hospitalization at themean age
of 47.1 6 21.1 months (range: 16–78
months). When SMA1 severity was
ranked in ventilated patients according
to age at the ﬁrst respiratory
decompensation,17 the proportion of
typical SMA1 with ﬁrst respiratory de-
compensation between 4 and 18
months of age was higher in the TV
group compared with NRA group (P =
.014).
When patients were considered over
a 6-year time period, the number and
percentageof patients assigned to each
groupchangedover the years as shown
in Table 3.
Theuseof TVdecreased from50%(1992–
1998) to 12.7% (2005–2010) (P = .0002),
with a nonsigniﬁcant increase for NT
from 50% to 64.6% (P = .304). NRA was
not available from 1992 to 1998; it
TABLE 1 Classiﬁcation of SMA1 Severity According to Age at Onset of Clinical Symptoms9
Groups Number and Proportion (%) of Patients
With SymptomOnset,3Months (True SMA1)
Number and Proportion (%) of Patients With
Symptom Onset .3 Months (Intermediate
SMA1)
NT (n = 121) 83 (68.5)a 38 (31.5)
TV (n = 42) 16 (38.1) 26 (61.9)
NRA (n = 31) 10 (32.2) 21 (67.8)
a NT versus NRA and TV, P , .01.
TABLE 2 Classiﬁcation of SMA1 Severity According to Age at First Respiratory Decompensation14
Group Number and Proportion (%) of Patients With
First Respiratory Decompensation Between
0 and 3 Months (Severe SMA1)
Number and Proportion (%) of Patients
With First Respiratory Decompensation Between
4 and 18 Months (Typical SMA1)
Number and Proportion (%) of Patients
With First Respiratory Decompensation After
18 Months (Mild SMA1)
TV(n = 42) 1 (2.3) 33 (78.5)* 8 (19)
NRA (n = 31) 5 (16.1) 15 (48.3)x 11 (35.4)
xNRA versus *TV, P , .05.
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successively increased from 8.1%
(1999–2004) to 22.7% (2005–2010) (P =
.021).
At the time of the study, 113 patients
(93.3%) had died at a median age of
6.95 (mean age: 8.1 6 5.3 months;
interquartile range: 5–10.1 months), 7
patients (16.7%) died at a median age
of 76.1 months (mean age: 85.66 46.7
months; interquartile range: 51.5–
113.1 months), and 14 patients (45.2%)
died at a median age of 28.6 months
(mean age: 31.6 6 21.3 months; inter-
quartile range: 12.8–41.4 months) in
the NT, TV, and NRA groups, re-
spectively. Survival at 24 and 48months
was higher in TV users than in NRA
users: 95% (95% conﬁdence interval
[CI]: 81.8%–98.8%) and 67.7% (95% CI:
46.7%–82%) at 24 months (P , .001)
and 89.43% and 45% at 48 months in
the TV and NRA groups, respectively
(P , .001). Some patients with mild
phenotypes in the NT group survived
beyond 24 months (1.3% [95% CI: 0.1%–
6%] survival in the NT group) (Fig 1).
Table 4 shows the number of re-
spiratory decompensations treated at
home or causing patient hospital
admissions. Among NRA patients, 7 were
eventually tracheostomized: 2 patients
(mean age: 226 0.5 months) after 10.1
6 0.5 months because parents were
unable to guarantee the continuous care
needed for NRA; 4 patients (mean age:
10.76 1 months) after 26 0.5 months
because of an incapability to manage
NRA in the presence of the continuous
need for bag andmask ventilation; and 1
patient (aged 67 months) after 59
months of NRA because of worsened
neurologic status after cardiorespiratory
arrest at home.
Fifty-two patients were still alive (896
43 months for TV and 38.2 6 21.4 for
NRA) at the time of data collection.
Hours per day of ventilator dependence
at data collection were 23.1 6 2.8 and
12.4 6 6.07 for TV and NRA groups,
respectively (P , .001).
In the TV group, all patients depended on
mechanical ventilation for 24 hours per
day; in the NRA group, only 2 patients
needed mechanical ventilation for 24
hours per day, while none needed me-
chanical ventilation for 18 hours per day.
DISCUSSION
Ourdata revealed that (1) patients in the
NTgrouphada lowersurvivalprobability
and died within the second year of life;
(2)bothTVandNRApatientshadahigher
survival probability compared with NT
patients, with a lower survival proba-
bility at 24 and 48 months and a higher
risk of death for the NRA group; (3) the
hours per day onmechanical ventilation
during the study period were signiﬁ-
cantly less in the NRA group, with just 2
patients being ventilated in the NRA
group.18 hours per day.
We observed more respiratory
decompensations and treatment fail-
ures in the NRA group, which required
TV in 7 patients. Importantly, 1 patient
suffered from a cardiorespiratory ar-
rest at the age of 5 years because of an
unsuccessful resuscitation followed by
severe neurologic damage. As already
suggested by Bach et al,10 acute re-
spiratory decompensation can be life-
threatening in SMA1 patients. In NRA
patients, there are also more difﬁcul-
ties in clearing airways and in per-
forming resuscitation maneuvers due
to bulbar dysfunction. Patients in the TV
group showed a trend toward fewer
respiratory decompensations and
emergency hospital admissions than
those in the NRA group. Although TV
does not completely protect the airway
because tracheotomy tubes are often
uncuffed, the likelihood of an efﬁcient
ventilation is doubtlessly easier in
patients in the TV group. These data
may indicate that NRA has several
limitations and cannot offer the same
probability of survival as TV. These data
are in contrast with those published in
other studies.9–11
Interestingly, in the NRA group, 6
patients (19.3%) did not show any epi-
sode of respiratory decompensation
and 11 patients (35.4%) had the ﬁrst
respiratory decompensation only after
the age of 18 months. This high in-
dividual variability was attributed to 1
TABLE 3 Number of Patients Assigned to
Each Group
Group Period
1992–1998 1999–2004 2005–2010
NT 5 (50) 45 (60.8) 71 (64.6)
NRA 0 (0) 6(8.1) 25(22.7)a
TV 5(50)b 23(31.1) 14(12.7)
Total 10 74 110
Data are n (%).
a 2005–2010 vs 1999-2004, P , .005.
b 1992–1998 vs 2005–2010, P , .005.
FIGURE 1
Kaplan-Meierestimates of survival in the 3groups. Thecumulative probability of survivalwasgreater for
continuous NRA and TV groups, with a lower survival probability at ages 24 and 48 months in the NRA
group.
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patient in need of NIV 24 hours per day
since birth and by 1 patient with the
ﬁrst episode of respiratory de-
compensation at the age of 42 months.
Last, at the time of data collection, only
2 out of 31 patients (7%) in the NRA
group were in need of NIV 24 hours per
day compared with 39 out of 42
patients (92%) in the TV group. These
data could indicate that patients
treated with NRA could have a milder
phenotype as recently suggested.22
Previous studies also found that tra-
cheostomy makes patients more de-
pendent on the ventilator.24
Mortality in ourcohort treatedwithNRA
was higher (45.2%) than that reported
by others.10–12,16 Bach et al11 reported
a mortality rate of 17% (8 of 47 treated
patients) in NRA patients aged 65.2 6
45months. A recent study from a single
Italian center also revealed that the
mortality rate was 14.2% in 16 NRA
users aged 40.5 6 18.1 months.12
However, the mortality rate was higher
in other studies.25–27 Chatwin et al,26 in
a study in children treated with NRA,
whose age was not reported, observed
a mortality rate of 38.4%. Mannaa
et al,27 using low levels of bilevel ven-
tilation, found no prolongation of sur-
vival with all deaths within the second
year of life, which was equal to that of
the untreated patient. Because the
mortality rates of the current study is
among these results, we can speculate
that differencesmay derive fromchanges
in treatment to NRA and an improved
learning curve over the years. Moreover,
NIV has gradually becomemore available
over the past 10 to 20 years in Italy,
which also affects treatment choice.
Our study has several limitations. First,
it was a retrospective case series;
however, to our knowledge, no ran-
domized controlled trial has been car-
ried out in SMA1 management up to
now.26 Second, we ﬁrst ranked SMA
severity according to Ioos et al8
because we lacked data on the age
at ﬁrst episode of respiratory de-
compensation of the nonventilated
patients. Third, NIV and MAC have been
used differently over the years among
the referring units, reﬂecting a possi-
ble nonhomogeneous ventilatory
treatment.28 Fourth, NT, NRA, and TV
groups were likely not homogeneous. It
is also possible that some patients af-
fected by severe disease had been
assigned to NRA to allow for compas-
sionate discharge from the hospital.
Fifth, tracheal ventilation or NRA
requires different levels of caregiver
expertise. It cannot be excluded that
some deaths in the NRA group could be
related to caregiver inexperience, in-
adequate training, or to a delay in
hospital admission. Sixth, our results
are from referral care hospitals with
experienced multidisciplinary teams.
Our results may not be applicable to
nonreferral centers.12 Seventh, clini-
cians at the different hospitals could
have presented the parents with the
choices in a different fashion. One
cannot exclude that children affected
by themost severe phenotypes induced
physicians and consequently parents
to choose for an NT strategy.25 However,
the number of “true” SMA18 patients
was higher in the NT group compared
with the TV and NRA groups, suggesting
a parental choice for NT because of
a worse quality of life in these children.
In conclusion, long-term survival out-
come can be determined by parents’
choice. NRA and TV presented as ther-
apeutic options can prolong survival,
with NRA showing a lower survival
probability at ages 24 and 48 months.
There is no ideal respiratory treatment
of patients with SMA1. NRA has several
limitations, some of which may be se-
vere, such as the risk of unsuccessful
resuscitation at home during re-
spiratory decompensations. In addi-
tion, the higher risk of hospitalization,
which may include intermittent patient
intubation, may impair quality of life for
the patient’s family and the patient’s
healthy siblings. These limitations are
not due only to caregivers’or clinicians’
inexperience but also to the severity of
the disease itself and the equipment
for NRA, which was originally designed
for teenage and young adult patients.29
We believe that our results may help
clinicians involved in the care of patients
with SMA1 to be more aware of survival
trends using different strategies.
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